Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Improving treatment of liver metastases by targeting nonangiogenic mechanisms

A recent study confirms an association between vessel co-option and resistance to bevacizumab, an anti-vascular endothelial growth factor-A (VEGFA) antibody, in patients with liver metastases. The authors suggest a combined therapeutic strategy that reduces co-option in mice.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1: Potential strategies for overcoming resistance to anti-VEGFA therapy.

Katie Vicari/Nature Publishing Group


  1. Jain, R.K. Cancer Cell 26, 605–622 (2014).

    Article  CAS  Google Scholar 

  2. Bergers, G. & Hanahan, D. Nat. Rev. Cancer 8, 592–603 (2008).

    Article  CAS  Google Scholar 

  3. Frentzas, S. et al. Nat. Med. 22, 1294–1302 (2016).

    Article  CAS  Google Scholar 

  4. Vermeulen, P.B. et al. J. Pathol. 195, 336–342 (2001).

    Article  CAS  Google Scholar 

  5. Donnem, T. et al. Cancer Med. 2, 427–436 (2013).

    Article  CAS  Google Scholar 

  6. Jeong, H.S. et al. J. Natl. Cancer Inst. 107, djv155 (2015).

    Article  Google Scholar 

  7. Stessels, F. et al. Br. J. Cancer 90, 1429–1436 (2004).

    Article  CAS  Google Scholar 

  8. Carmeliet, P. & Jain, R.K. Nature 473, 298–307 (2011).

    Article  CAS  Google Scholar 

  9. Rahbari, N.N. et al. Sci. Transl. Med. 8, 360ra135 (2016).

    Article  Google Scholar 

  10. Gilkes, D.M., Semenza, G.L. & Wirtz, D. Nat. Rev. Cancer 14, 430–439 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Kyrre E Emblem.

Ethics declarations

Competing interests

K.E.E. has no conflicts of interest. E.K.J. has received consultant fees from Enlight, Ophthotech, SPARC and SynDevRx, owns equity in Enlight, Ophthotech, SynDevRx and XTuit, and serves on the Board of Directors of XTuit and the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. No funding or reagents from these companies were used in this study.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Emblem, K., Jain, R. Improving treatment of liver metastases by targeting nonangiogenic mechanisms. Nat Med 22, 1209–1210 (2016).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer